N/A
Completed N=200
SEEQ™ Performance Study
Arrhythmia Type Unknown
Source: ClinicalTrials.gov NCT02484898 ↗
Enrolled (actual)
200
Serious AEs
0.0%
Results posted
Nov 2016
Primary outcomePrimary: Diagnostic Yield of the SEEQ™ MCT/ECM System — 85.7 percentage of subjects with CRA
Summary
The purpose of the Medtronic SEEQ™ Performance study is to build further evidence on the clinical and economic benefit of the Medtronic market-released SEEQ™ Mobile Cardiac Telemetry System/External Cardiac Monitor System (MCT/ECM).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Diagnostic Yield of the SEEQ™ MCT/ECM System |
85.7 | — |
Eligibility Criteria
Inclusion Criteria
- Patient is indicated for a SEEQ™ MCT/ECM System for approved indications
- Patient is 18 years of age or older
- Patient is willing and able to provide consent and authorize the use and disclosure of health information
- Patient is willing and able to comply with the protocol
Exclusion Criteria
- Patient has known allergy and/or hypersensitivity to adhesives or hydrogel.
- Patient has suspected potential life-threatening arrhythmias, or requires in-subject/in-hospital monitoring.
- Patient will undergo a medical procedure that would preclude full participate during the prescribed duration of the SEEQ™
- Patient has an implanted cardiac device, (e.g., pacemaker, Implantable Cardioverter Defibrillator, Cardiac Resynchronization Therapy)
Data sourced from ClinicalTrials.gov (NCT02484898). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.